expert reaction to study looking at creating embryo-like structures … – Science Media Centre

April 6, 2023

A study published in Cell Stem Cell looks at the generation of embryo-like structures from monkey embryonic stem cells.

Prof Magdalena Zernicka-Goetz, Bren Professor of Biology and Biological Engineering, California Institute of Technology; and Professor of Mammalian Development and Stem Cell Biology, University of Cambridge, said:

This is an exciting development building on work from our own and other labs showing the importance of establishing interactions between embryonic and extra-embryonic stem cells to establish models of the mammalian embryo at pre-and early post-implantation stages. The excitement of this study is not only that embryos generated from monkey stem cells provide a close model for human embryos, but monkeys are also experimentally tractable.

The authors follow approaches that have been previously used to direct embryonic stem cells into a naive state, and then use treatments that allow the nave monkey ES cells to form extra-embryonic cell types. Together these cells assemble into blastoids, structures resembling blastocysts, that are able to develop in vitro into structures with a striking resemblance to the embryonic disc at gastrulation, both in morphology and gene expression. The blastoids also appear to implant into foster monkey mothers but, in common with similar structures in the mouse, development appears restricted.

This study is a hugely encouraging development in the study of primate embryo models.

The paper is excellent and an important step forward but still the stem cell derived embryos have a limited developmental potential, as the authors state themselves. Nevertheless, it is an important step in the very exciting field of enormous potential for understanding how the embryo develops and why so many pregnancies fail.

Prof Roger Sturmey, Professor of Reproductive Medicine, Hull York Medical School, University of Hull, said:

The work by Li and colleagues is an impressive technical achievement that has demonstrated the possibility that embryonic stem cells from a primate can be persuaded to form structures that mirror many features of early embryos.

Similar achievements have already been reported in other species, however this work assesses the primate embryo-like structures in detail and gives new insights into how the cell lineages families of cells that constitute the early embryo can be generated from stem cells.

Remarkably, when cultured in a laboatory, the embryo-like structures are able to replicate a number of key developmental features, most notably the formation of cells that resemble the primordial germ cells the cells that can produce gametes as well as the formation of a structure similar to the so-called primitive streak. When transferred into a recipient macaque uterus, these embryo-like structures were able to generate components of a pregnancy response, but were unable to develop, indicating that while these structures do share many features with competent embryos, there are still aspects of early development that differ between competent embryos and stem-cell derived models, preventing full development.

The work by Li and colleagues will offer important new tools in our understanding of the earliest stages of embryo development, but also highlight the need for guidance in this area, something that scientists in the UK are actively working on.

Prof Alfonso Martinez Arias, ICREA Senior Research Professor, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), said:

This is a timely study.

About half of human pregnancies fail during the proliferation of the zygote and the implantation of the blastocyst. Understanding the causes of this failure rate will impact human fertility and IVF success. In part to address this need, over the last few years, a number of Embryonic Stem (ES) cell models of early mammalian development have been created in the lab. Amidst these, mouse and human blastoids mimic mammalian blastocysts and as such can play an important role in understanding the process of implantation. Blastoids have been derived from mouse and human ES cells.

For these studies to go forward there is a need to develop a proper test for the function of the blastocyst: its implantation into the uterus. In the case of mouse blastoids this can be tested by implanting them into females. However, there is no such a test for human blastoids since, for obvious reasons, it is not possible to implant them into a human uterus. And yet there is a need to develop a system to study these structures in humans. Mouse reproductive biology and implantation are very different from human, which means that while an excellent system to find principles, the mouse is not useful for the specifics of this process; and this is what matters. It is this vacuum of a system to study human implantation and peri-implantation development that is addressed in the present study.

Following protocols established for human blastoids, macaque blastoids are made from nave stem cells and their potential is tested in two ways. One, by culturing them in vitro up to gastrulation stages and the other, by placing them in the uterus of a macaque foster mother. The idea behind this system is that it has reduced ethical barriers compared to human and therefore might provide an experimental system to test the potential of blastoids fully and, in the long term, to study infertility. The work is well conducted and the result is clear: although at the level of single cells macaque blastoids bear a strong resemblance to blastocysts, they do not behave as blastocysts. Although they implant and initiate gastrulation, they do not reach the end of this process. In vitro, blastoids cultured to form an epiblast and to undergo gastrulation, display progressive problems over time and, though they reach early stages of gastrulation, it is difficult to see in their data how faithful they are to an early gastrula. In one important experiment they implant some of these into female macaques and follow their progress with ultrasound. It appears as if they might perform well in the early stages of implantation, and the release of progesterone is a sign that something has gone well, but then, they disappear after about a week.

So, the important result of this work is that we are not close to generating blastoids that can be recognised as blastocysts by the mother. Definitely an important proof of principle but the lesson is that there is work to do.

An important difference between a blastoid and a blatocyst is their origin. The blastocyst in the egg, the blastoid in the ES cells. There might be elements in the oocyte that are important for the viability of the blastocysts and that will not be provided by the ES cells. Furthermore, if about 50% of conceptions fail at implantation, it is difficult to gauge whether the failure of the high level goal of the experiment (long term development in the womb) is due to defects in the blastoid system or whether the failure mirrors the natural situation; eight experimental subjects, the numbers of the experiment, are not sufficient to make a judgement. Only more experiments will decide and the one reported here, within well established ethical footprints, is definitely one to watch.

Dr Darius Widera, Associate Professor in Stem Cell Biology and Regenerative Medicine, University of Reading, said:

This is an interesting study that demonstrates the successful generation of embryo-like structures from monkey embryonic stem cells. These structures resembled natural early embryonic structures and could generate cell types of all three germ layers. Although similar studies have been conducted using human stem cells, this is the first report showing that (in this case, monkey) embryo-like structures can induce signs of pregnancy if transplanted into females. Therefore, the method could be used as a model of primate and human development and potentially provide new insights into certain factors that contribute to miscarriages in humans.

However, the study has some limitations. Only 3 out of 8 embryo-like structures were successfully implanted into female monkeys, and none of these persisted for more than one week. Thus, the structures do not have full developmental potential.

In addition, the ethical implications of embryonic stem cell research in monkeys are complex. Primates are intelligent, social animals with complex cognitive and emotional lives. Therefore, it is important to carefully consider both the potential benefits and the ethical impact of primate embryonic stem cell research.

Prof Robin Lovell-Badge FRS FMedSci, Group Leader, Francis Crick Institute, said:

The paper by Jie Li et al is another demonstration of the remarkable ability of pluripotent stem cells, in this case embryonic stem cells derived from early Macaque (non-human primate) embryos, to self-organise and begin a process of embryo formation in culture that mirrors that of normal Macaque embryos. However, the paper also shows that these stem cell-based embryo models are not entirely normal they could be implanted in female macaques, appear to initiate a pregnancy, but then fail soon after.

The authors were able to culture these stem cell-based embryo models, which they refer to as blastoids, through to gastrulation stages, equivalent to post-implantation embryos developing in a uterus, with good signs of development of all the main extraembryonic and embryonic tissues, where the latter included ectoderm, mesoderm and endoderm organised in a similar fashion to normal embryos. They could also demonstrate the presence of primordial germ cell-like cells and cells that are early progenitors of the blood system. These stages would be equivalent to those of human embryos at about 16 -18 days of development, beyond the 14 day limit (or the beginning of gastrulation) which is the maximum period normal human embryos are allowed to be cultured by law in the UK and some other countries.

It has been shown by others that human pluripotent stem cells can also be used to form blastoids, but to date such cultures have been stopped prior to gastrulation, but the paper by Li et al suggests that they could indeed be taken beyond this and provide valuable information about these early stages of human development that are otherwise very difficult to obtain. The data from the Macaque embryos and blastoid cultures may also help to understand aspects of human development, but without direct comparisons this will always be tentative, given how much mammalian embryos can vary at these stages.

These embryo models are referred to as integrated stem cell-based embryo models because they include extraembryonic tissues that normally give rise to the placenta and yolk sac that in a normal conceptus would permit implantation into the uterus and support the development of the embryo proper. So how much like a real embryo are these Macaque blastoids and could they implant and develop much further in a uterus? Although all the detailed comparisons presented in the paper of gene expression in the various cell types between normal Macaque embryos and the embryo models suggests that they can be very similar, the proportion of the blastoids reaching advanced stages was very low, indicating that most are not normal, and those that did still showed some differences. Moreover, while some could implant, begin to develop some complexity, and induce a typical response in the host uterus and lead to production of the typical pregnancy hormones, chorionic gonadotrophin and progesterone, the embryos all failed before gastrulation. This suggests that they failed to form fully functional extraembryonic tissues that could adequately support the embryo and that these could not give rise to a placenta, which would be essential for more complex development. It is likely that the same would be true for human integrated stem cell-based embryo models, although it would be unethical and illegal (in the UK) to attempt to implant these into a woman.

It seems likely that the culture methods for these integrated stem cell-based embryo models will be improved, and who knows it may eventually be possible to have them implant and develop normally, but the failure of this to happen as reported in this paper will give regulators some breathing space to develop appropriate rules for the culture of such human models, notably whether they can be taken beyond the equivalent of gastrulation stages, which would be of immense importance in helping to understand not just normal development of the human embryo, but what so often goes wrong and leads to embryo failure and congenital disorders.

Cynomolgus monkey embryo model captures gastrulation and early pregnancy by Jie Li et al. was published in Cell Stem Cell at 16:00 UK time on Thursday 6 April 2023.

DOI: 10.1016/j.stem.2023.03.009

Declared interests

Prof Magdalena Zernicka-Goetz: I have no conflict of interest to declare.

Prof Roger Sturmey: None.

Prof Alfonso Martinez Arias: I have no conflict of interests.

Dr Darius Widera: I have no conflict of interest to declare.

Prof Robin Lovell-Badge: I have no conflicts of interest to declare, except I do serve on the HFEAs Scientific and Clinical Advances Advisory Committee and I am a member of their Legislative Reform Advisory Group.

Continue reading here:
expert reaction to study looking at creating embryo-like structures ... - Science Media Centre

NANOG (Part 1): Its Role In Aging And Cancer – Forbes

eternal youth and the mythological island that NANOG protein was named after.Patrick Lynch, URL: https://www.irishcentral.com/roots/history/tir-na-nog-legend-eternal-youth

This is the first article in a series on the NANOG protein. Please see my companion series on klotho, another protein that may be involved in aging. You can read more about klotho in parts 1 and 2 of my series.

In Celtic mythology, Tr na ng is an island paradise and supernatural realm filled with everlasting youth, beauty, health, abundance, and joy. The inhabitants of Tr na ng consist of warriors and gods who are known for their poetry, music, and entertainment. By participating in the feast of Goibniu, the inhabitants of the island are granted immortality, giving Tr na ng its nickname The Land of Youth.

Now, studies report that a protein named after this Celtic taleNANOG may play a role in anti-aging and cancer prevention, but what is NANOG and why do researchers believe that it may prevent aging?

What is NANOG?

The key to NANOG and its biological function lies in our embryonic stem cells. Stem cells are a unique cell type, containing two characteristics that make them very powerful: pluripotency and the ability for self-renewal.

Pluripotency is the ability of stem cells to develop into many different tissues or cell types. While all embryonic stem cells are essentially the same basic cell, each stem cell has the potential to grow into nearly any tissue or cell type in the body. In other words, a single stem cell has multiple fates and depending on the environmental and chemical cues the stem cell is given, it can become anything from a brain cell to a muscle cell.

This becomes an especially important property when considering that stem cells have the ability to self-renew. Unlike many other cells, embryonic stem cells can simply divide to create multiples of themselves, allowing them to exist perpetually in the body so long as they can continue to self-renew.

What allows these stem cells to not only constantly regenerate, but to maintain their pluripotency? In other words, when new stem cells are created, what prevents them from spontaneously maturing into some form of adult cell?

Both pluripotency and self-renewal have been linked to a few, core transcription factors. Transcription factors are proteins in the body that control whether genes are turned on or off. Previous studies have found that the core transcription factors controlling stemness are Oct4, Sox2, Klf4, and NANOG.

How NANOG maintains pluripotency and self-renewal

An interesting aspect of NANOG is that it does not exist in adult cells. Instead, NANOG is only detected in stem cells that are still pluripotentthey have not begun to differentiate or develop into any particular cell type. Once a stem cell begins to differentiate, the NANOG gene is turned off and NANOG protein is no longer produced in the cell. Due to this observation, scientists suggest that NANOG may play a role in maintaining the pluripotency of stem cells, essentially preventing the stem cells from differentiating and maturing into adult cells.

There are three NANOG proteins that influence the pluripotency of human embryonic stem cells. These are Nanog1, Nanog2, and NanogP8. Researchers have found that when Nanog1 is abundant, it can prevent embryonic stem cells from differentiating. When the protein is scarce, embryonic stem cells tend to mature and differentiate into other cell types, losing their pluripotency.

NanogP8 is similar to Nanog1 except that it is mainly found in cancer cells, suggesting that NanogP8 may have larger anti-cancer properties than anti-aging properties.

How exactly could NANOG prevent stem cells from differentiating? While it is currently unclear what the biological mechanisms of NANOG are, two proteins that might offer a clue are leukemia inhibitory factor and STAT3. Both leukemia inhibitory factor proteins and STAT3 are widely known to prevent the differentiation of stem cells.

Leukemia inhibitory factor plays an important role in a wide array of biological processes including the growth of leukemia cancer cells and inflammation. The protein works primarily by controlling the activity of other transcription factors and proteins including STAT3. Researchers have found that when leukemia inhibitory factor levels drop and STAT3 activity decreases, stem cells begin to differentiate.

Interestingly, more recent experiments have shown that when NANOG is deficient, stem cells also differentiate. This occurs even in the presence of STAT3 and leukemia inhibitory factor, suggesting that NANOG may help maintain the pluripotency of stem cells by controlling the production and release of leukemia inhibitory factor and STAT3.

Additional studies focus on how NANOG may interact with other core transcription factors like Oct4 to prevent the differentiation of stem cells and maintain pluripotency. Researchers have suggested that NANOG and Oct4 may work together to control certain genes and proteins related to the pluripotency of stem cells. Oct4 is a transcription factor that is critically involved in the self-renewal of embryonic stem cells. Studies have shown that NANOG and Oct4 exhibit very similar patterns of behavior and often regulate similar genes in the body. This has led to the suspicion that NANOG and Oct4 may play a combined role in maintaining the pluripotency and self-renewal of embryonic stem cells.

Conclusion: NANOG in aging and cancer

While the biological mechanisms of how NANOG maintains the pluripotency of stem cells are unclear, it is evident that this small protein has an unusual ability to determine whether or not cells mature into different cell types. In the next installments of this short series, I will detail some of the more recent studies on NANOG, how the protein may prevent cellular aging, and how it could play a role in minimizing the growth of cancerous tumors.

I am a scientist, businessman, author, and philanthropist. For nearly two decades, I was a professor at Harvard Medical School and Harvard School of Public Health where I founded two academic research departments, the Division of Biochemical Pharmacology and the Division of Human Retrovirology. I am perhaps most well known for my work on cancer, HIV/AIDS, genomics and, today, on COVID-19. My autobiography, My Lifelong Fight Against Disease, publishes this October. I am chair and president of ACCESS Health International, a nonprofit organization I founded that fosters innovative solutions to the greatest health challenges of our day. Each of my articles at Forbes.com will focus on a specific healthcare challenge and offer best practices and innovative solutions to overcome those challenges for the benefit of all.

See the original post:
NANOG (Part 1): Its Role In Aging And Cancer - Forbes

Stem Cell Therapy Market Size is Estimated to Increase USD 44.5 … – GlobeNewswire

New York, April 11, 2023 (GLOBE NEWSWIRE) -- Market.us research reveals that The global stem cell therapy market size was estimated at USD 11.1 billion in 2022 and is expected to reach around USD 44.5 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 15.3% during the forecast period 2022 to 2030. Stem cell therapy is used to transplant stem cells; in this therapy, stem cells are changed by chemotherapy. Stem cell therapy contains types like Hematopoietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), Skin Stem Cells (SSCs), and Neural Stem Cells (NSCs). Chemotherapy act as an immune system to face disorders linked to blood or cancer, such as multiple myeloma, neuroblastoma, lymphoma, and leukemia. The cost of each stem cell therapy method can vary between 5,000$ and 50,000$.

Identify key trends, drivers, and challenges in the stem cell therapy market, which will help vendors improve their strategies to stay ahead of their competitors. View our PDF Sample Report - https://market.us/report/stem-cell-therapy-market/request-sample/

Key Takeaway:

The stem cell therapy market increased owing to a lot of investment in stem cell research, various clinical trials related to stem cell therapy, and an increasing number of cell therapy production facilities. Several cell therapy clinical trials were done during the epidemic due to the various benefits of stem cell therapies.

Factors affecting the growth of the Stem Cell Therapy industry?

There are several factors that can affect the growth of the neonatal intensive care respiratory devices industry. Some of these factors include:

Interested to Procure the Data? Inquire here at -https://market.us/report/stem-cell-therapy-market/#inquiry

Top Trends in Global Stem Cell Therapy Market

The global cancer load is increasing. Hence, cancer therapies must be updated with regional and national priorities. Breast, lung, cervical, colorectal, and thyroid cancers are common among women. However, lung cancer and prostate cancer are the more frequent among men which, acquired a share of 33% of male cancer.

A stem cell transplant is a treatment for cancer types such as leukemia, neuroblastoma, multiple myeloma, or lymphoma types. Autologous transplants are favored in the cases such as leukemia, testicular cancer, multiple myeloma, lymphomas, and neuroblastoma. Autologous and allogeneic stem cell transplants can both be used for cancer treatments.

Regional Analysis

North America dominated the market share of the global stem cell therapy market, with 35% of this market in 2022. The most recent advanced technologies, considerable governmental & private investment, and economic expansion help to benefits the market region. The presence of the latest research infrastructure, rising R&D efforts to form chronic diseases therapeutic choices, and ordinary clinical trials review process for driving the market elements in the region. Key research organizations and market suppliers located in the United States receive large funding. Various projects in the region's pipeline are increasing consumer demand.

Due to an increase in the need for stem cell therapy and a rising prevalence of chronic and neurological diseases, Europe acquired the second-highest market share. The cell therapy in Asia-Pacific market growth is increasing at the highest growth rate because of its fast growth and several companies arrival in APAC. Moreover, the APAC region's increasing use of stem cell therapy and rising cancer dominance are projected to stimulate market expansion.

For more insights on the market share of various regions - Download a Sample Report

Scope of the Report

Market Drivers

The efficient treatment demand is increasing due to the rising chronic disease rate. In the COVID-19 epidemic, chronic diseases such as heart disease, cardiovascular disorder, cancer, neurological disorder, stroke, and respiratory illnesses place a big stress on society. Four of the ten adults have greater than two chronic diseases, and six of ten adults have at least one chronic disease. These show how diseases are dominating as well as how nicely they are managed. Clinical trials are expected to raise stem cell demand during the forecast period.

Market Restraints

Although research on stem cells is very promising for the medical sector, its expansion is restrained due to ethical issues by a regulatory bodies. The devastation of the human embryonic stem cell is the main issue that might have foiled the development of stem cell research.

Market Opportunities

The banking of stem cells need is rising as the number of chronic disorders and genetic abnormalities has increased. An increasing firm has stepped into the stem cell banking sector due to rising public awareness of stem cell therapy. To boost sales and market for stem cell therapy, adult stem cells, which are genetically programmed, are using embryonic stem cells called pluripotent stem cells.

Grow your profit margin with Market.us - Purchase Stem Cell Therapy Premium Market Report athttps://market.us/purchase-report/?report_id=12272

Report Segmentation of the Global Stem Cell Therapy Market

Cell Source Insight

The largest market share was dominated by adipose tissue with 34% market share in 2022. Because source of this cell is used in adipose tissue, which is a specialized connective tissue containing lipid-rich cells known as adipocytes. These adipocytes are mainly discovered in the skin and deposit among the muscles, intestines membrane folds, inside the intestines, near the heart, and other places. Moreover, the global stem cell therapy market share depends on cell source types segmented into IPSCs, neural, PPSCs, embryo/cord, adipose tissue, and bone marrow.

Type Insight

The global stem cell therapy market is growing because the largest market share was occupied by the allogenic segment, with a 74% market share in 2022, owing to its increasing incidence of cancer and other related disorders. The global stem cell therapy market share is based on the type segregated into allogenic stem cell therapy and autologous stem cell therapy. According to the WHO, children of ages 0 to 19 are diagnosed with almost 300K new cases of cancer annually. In 2022, there will be 21 million new cases of cancer, according to estimates. This puts a strain on the global healthcare system and increases the demand for cancer treatments that are efficient anywhere in the world.

Application Insight

The largest market share was dominated by the diabetes segment, with a 28% market share in 2022. Because 450 million people are infected by diabetes across the globe, from WHO report. Diabetes is normal in several countries for individuals of low and medium incomes. The global stem cell therapy market is based on applications segmented into cardiovascular, diabetes, cancer, musculoskeletal disorders, and gastrointestinal diseases. Furthermore, the diabetes segment, also called diabetes mellitus of metabolic disease that is infested when blood glucose levels are too high. Over time period, diabetes disorder can cause a lot of harm to the kidneys, eyes, blood vessels, heart, and eyes.

End User Insight

The largest market share was dominated by the hospitals & clinics segment, with a 28% market share in 2022 because of the rising occurrence of skin conditions like acne. The global stem cell therapy market is based on end-user types segmented into hospitals & clinics, academic & research centers, ambulatory surgical centers, and other end users.

Drivers and challenges have an impact on market dynamics and can impact businesses. Find some insights from a sample report: https://market.us/report/stem-cell-therapy-market/request-sample/

Market Segmentation

By Cell Source

By Type

By Application

By End User

By Geography

Competitive Landscape

With the presence of many local and regional players, the market for global stem cell therapy market is fragmented. Market players have intense competition from prominent key players, mainly those with big recognition of the brand and high networks for distribution. Companies have started various expansion strategies to gain a top spot in the market, such as partnerships and product launches.

The competitive landscape of the market has also been examined in this report. Some of the major players include

Recent Development of the Stem Cell Therapy Market

Browse More Related Reports:

About Us:

Market.US(Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicatedmarket research report-providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us On LinkedIn Facebook Twitter

Our Blog:

Read more from the original source:
Stem Cell Therapy Market Size is Estimated to Increase USD 44.5 ... - GlobeNewswire

Regenerative Medicine Market Investments, Share and Revenue … – GlobeNewswire

Jersey City, NJ, April 12, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "GlobalRegenerative Medicine Market Size, Share & Trends Analysis Report By Product (Therapeutics, Primary cell-based therapeutics, Stem Cell & Progenitor Cell-based therapeutics), By Therapeutic Category (Dermatology, Musculoskeletal, Immunology & Inflammation, and Oncology)- Market Outlook And Industry Analysis 2031"

The global Regenerative Medicine market is estimated to reach over USD 183.08 billion by 2031, exhibiting a CAGR of 15.02% during the forecast period.

In recent year, it has been determined that regenerative therapies can uniquely change the underlying pathological processes. Trial-stage regenerative medicines offer promising treatments for particular chronic diseases with unmet medical needs. Novartis announced the release of T-ChargeTM in December 2021, a next-generation CAR-T platform that would be used for cutting-edge investigational CAR-T cell treatments.

Free PDF Report Brochure @https://www.insightaceanalytic.com/request-sample/1687

The development of gene-based treatment, which uses targeted DNA delivery as a drug to combat numerous illnesses, results from significant effects in molecular therapeutics. With the restoration of gene function, gene therapy holds great promise for treating cancer and type 1 and type 2 diabetes. Gene-based medicines treat patients with conditions such as cancer, oncology, infectious diseases, cardiovascular disorders, monogenic diseases, genetic disorders, ophthalmological indications, and central nervous system illnesses. These elements have helped the market for regenerative medicine expand.

Recent Developments:

In April 2022, Obecabatagene autoleucel, a CD19-directed autologous chimeric antigen receptor T therapy being investigated in the ongoing FELIX Phase 2 study of leukaemia, has been given the Regenerative Medicine Advanced Therapy designation by the U.S. Food and Drug Administration (FDA). This was announced by Autolus Therapeutics plc.

List of Prominent Players in the Regenerative Medicine Market:

Get Customized Report @https://www.insightaceanalytic.com/customisation/1687

Regenerative Medicine Market Report Scope:

Market Dynamics:

Drivers- The ability of adult stem cells to proliferate or self-renew forever and to develop all the cell kinds of the organ from which they originate has propelled research into these cells, with the potential to regenerate the complete organ from a few cells. No embryo must be destroyed in order to produce adult stem cells. Furthermore, medical research on stem cells has been thoroughly examined and attracted much attention. ExCellThera Inc. and Ossium Health recently announced a partnership to explore and advance opportunities to use adult stem cells from deceased donors from Ossium Health's first-ever bone marrow bank in combination with ExCellThera's ECT-001 cell expansion and rejuvenation technology. This collaboration will take place in April 2021. These kinds of developments are anticipated to accelerate market expansion.

Challenges:The market for regenerative medicine is projected to be hampered by a lack of information and moral considerations surrounding the usage of embryonic stem cells for research and development. Since cell therapy is a crucial component of regenerative medicine, it has a significant impact on the market growth rate. One of the leading market inhibitors may be the high cost of investment, which might be followed by problems with assay sensitivity, robustness, and reproducibility; the challenge of culture/propagation; and finally, the challenge of handling.

Regional Trends:Due to the presence of big players, the rapid advancement of technology, significant investments in stem cell and oncology research, and the presence of major players, North America is predicted to have the largest revenue share. The largest market in North America is the United States. In the U.S., numerous stem cell therapies are increasingly being used to treat a growing number of ailments like cancer and diabetes. According to the Heart Disease & Stroke Statistics Fact Sheet 2020, congenital heart abnormalities are predicted to affect at least 40,000 infants annually in the United States.

Enquiry Before Buying @https://www.insightaceanalytic.com/enquiry-before-buying/1687

Segmentation of Regenerative Medicine Market-

By Product-

By Therapeutic Category-

By Region-

North America-

Europe-

Asia-Pacific-

Latin America-

Middle East & Africa-

About Us:

InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.

Follow Us @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Subscribe Our Exclusive Newsletters @ https://www.linkedin.com/newsletters/latest-market-research-reports-6929319878155739136/

Read the original here:
Regenerative Medicine Market Investments, Share and Revenue ... - GlobeNewswire

Bourbonnais toddler beats leukemia with stem cell transplant – Kankakee Daily Journal

While watching 3-year-old Mads Pomranky excitedly play on a Tuesday afternoon with his 1-year-old sister, Valen, one would never guess the difficult health struggles hes overcome.

At 5 months old, Mads was diagnosed with juvenile myelomonocytic leukemia, a rare cancer of the blood that affects young children. The diagnosis eventually turned to acute myeloid leukemia and was treatable only through a transplant from a stem cell donor.

For parents Jennifer and Derrick Pomranky, of Bourbonnais, they made the immediate decision to approach the challenge with positivity, designating their son Mighty Mads.

Its pretty difficult to watch your little baby go through this, Jennifer said. I feel like right away, we both had the mentality of, Hes gonna get through this, were gonna get through this.

We got through it one day at a time, added Derrick.

As an infant, Mads was often sick with congestion or runny nose. It was a pediatrician, Dr. Josefina Batista at Riverside Healthcare, that noticed his spleen was enlarged. Further testing would show his red blood cell count being low while his white cell count was high. These red flags led to the eventual leukemia diagnosis.

His pediatrician caught it so fast that we had time on our side that they could pinpoint the diagnosis and take their time with the chemo and wean him into it a little bit, said Jennifer while flipping through a book the family made for Mads donor. The book details Mads journey with cancer and treatment.

The book documents that Mads had six rounds of chemo, 83 doses of chemo, 31 blood transfusions, 31 platelet transfusions, 11 bone marrow biopsies, five spinal taps with chemo, two skin biopsies and one cryo transfusion.

His parents noted they were lucky in the search for a donor, as Mads health care team found a 10 out of 10 match through the stem cell/bone marrow transplant registry, DKMS.

The donation was from a young woman, Kaelynn Speed, out of Cincinnati.

Weve been an advocate for [DKMS], Jennifer said, noting that the DKMS shirts her kids were wearing were given to the family when they first met Speed through a donor meeting facilitated by the donor registry.

By the time doctors were able to begin providing transplant care to Mads then 13 months old the world was in the throes of COVID-19. As a result, Speeds cell donation had to be frozen for two weeks before being administered to Mads.

Mom Jennifer said that the process took about an hour and was similar to a blood transfusion.

Now, Mads has to have bloodwork done every three months to make sure everything is on the up and up. Additionally, he does a survivorship follow up at Comer Childrens Hospital, where he had his treatments.

Hes doing great. Hes very rambunctious and a normal toddler, said Jennifer.

Born May 16, 2019, Mads now has double the annual celebrations first, his birthday, and second, what his parents have dubbed his rebirthday on June 17, which is when he had the transplant.

Before and after transplant, he was really sick, Derrick said. So that was a bad time.

When he was going through all of it, he missed a lot of his milestones. He was basically reborn again, added Jennifer.

LIFE AND DEATH

The family still keeps in touch with Speed and her family; they received her information on the one-year anniversary of Mads transplant and set up a Zoom meeting. The families met in person last summer.

Shes the nicest person, she was only 19 when she signed up [to donate], Jennifer said. Derrick added that shes studying nursing.

Between work and two toddlers, the Pomranky parents certainly have their hands full, but they always make time to encourage people to sign up to be stem cell and/or bone marrow donors.

You could potentially save a life, Jennifer said. Its a matter of life and death, literally.

Excerpt from:
Bourbonnais toddler beats leukemia with stem cell transplant - Kankakee Daily Journal

Invasive aspergillosis: Symptoms and more – Medical News Today

Aspergillosis is an infectious disease that occurs due to a common type of fungus, or mold, called Aspergillus. A type of aspergillosis called invasive aspergillosis particularly affects people with weakened immune systems.

Most individuals breathe Aspergillus spores daily and do not develop any health effects.

However, people with compromised immune systems, such as those who have had an organ transplant or are undergoing chemotherapy treatment, may be at greater risk of developing aspergillosis.

The disease usually affects the lungs but can spread to other areas of the body.

This article looks at invasive aspergillosis and its symptoms, diagnosis, outlook, and more.

Aspergillus mold is common indoors and outdoors and can cause infection in the sinuses and lungs of immunocompromised people.

If the infection spreads to the rest of the body, outcomes are very unfavorable and include death.

Experts do not know the extent of aspergillosis in the United States, as it is not a reportable infection. However, according to a database of insurance claims, there were almost 15,000 hospitalizations for this diagnosis in the U.S. in 2014.

That said, the number of people with aspergillosis has likely increased since then.

Invasive aspergillosis is less common than the milder, allergic forms of the disease. It is the most common fungal infection in people who have had stem cell treatment. It is also the second most common in those who have received solid organ transplants.

Invasive aspergillosis usually occurs in people with weakened immune systems who often already have other medical conditions. Therefore, it can be difficult to differentiate between the symptoms of the infection and those of the underlying illness.

The symptoms of invasive aspergillosis may include:

Types of invasive aspergillosis include:

Other types of aspergillosis include:

A person can develop aspergillosis by breathing in Aspergillus spores, which are common in indoor and outdoor environments.

Most people will not get sick from breathing the spores, but those with weakened immune systems are at greater risk of infection.

People at risk of invasive aspergillosis include individuals with weakened immune systems, such as those who have received:

Additionally, hospitalized patients with severe influenza and those with HIV are at risk of invasive aspergillosis.

To diagnose aspergillosis, a doctor may examine a persons medical history and risk factors and ask questions about their symptoms.

They may perform a physical examination and several laboratory tests. These may include:

Doctors may treat invasive aspergillosis with several different antifungal medications.

These may include:

Where possible, doctors may also decrease or discontinue immunosuppressive medications to help treat invasive aspergillosis.

Because Aspergillus spores are common in the environment, it is difficult for people to avoid breathing them in.

Experts recommend those with weakened immune systems take certain measures to protect against the fungus. However, these actions may not prevent aspergillosis.

Preventive measures may include:

The outlook for invasive aspergillosis is generally unfavorable.

The mortality rate of invasive pulmonary aspergillosis is about 20% six weeks after diagnosis, despite treatment with antifungal medications.

The mortality rate reaches close to 100% once the infection has spread to the central nervous system.

Most people safely breathe Aspergillus spores every day, as these are common in indoor and outdoor environments.

However, those with weakened immune systems may be at risk of developing health problems from breathing microscopic amounts of the fungus.

In immunocompromised people, such as those undergoing chemotherapy or those who have had stem cell or organ transplants, invasive aspergillosis may affect the lungs and sinuses. This can cause symptoms such as shortness of breath and coughing up blood.

The disease may spread to other areas of the body and is often fatal once it reaches the central nervous system.

Treatment for invasive aspergillosis typically includes the use of antifungal medication.

Doctors may advise high risk individuals who are immunocompromised to take measures that may help prevent aspergillosis. These approaches include wearing protective equipment and clothing, testing, and taking antifungal drugs.

See the article here:
Invasive aspergillosis: Symptoms and more - Medical News Today

How artificial intelligence can help primary care doctorsand their … – Medical Economics

Two letters. Theyre enough to give your patients more anxiety than any treatment, test or injection. A recent survey by the Pew Research Center shows it: Sixty percent of Americans said they would be uncomfortable with their provider relying on artificial intelligence (AI) in their own health care. But when used responsibly, artificial intelligence can help primary care doctors expand their care while cutting costs in their practices. And patients will notice the difference tooeven if they dont realize the technology behind their improved experience is the result of those dreaded two letters.

Informed patients, informed doctors

What really scares patients is the idea of AI performing the skilled work of doctors. The fact is, however, we are a long way from AI replacing doctors. Nor will AI replace office staff. But we are now at a point where AI can start to address the communication issues doctors face in their practices.

Patients say they dont want AI making health care decisions for them based on its interpretation of their conditions, but AI can help patients navigate through the treatment process and get them information a lot faster. For example, doctors can use AI and chatbots in their patient engagement strategy to better understand their patients, send them personalized information that is tailored to their treatment journey, and create interactions that are relevant to their personal needs.

AI has numerous applications for primary care physicians who are looking to manage their patients health proactively, Jonathan Sachs, MBA, vice president and chief experience officer for Robert Wood Johnson University Hospital, told me. AI can unlock a physicians ability to understand a patients needs beyond their 15-minute office visit by helping that physician make sense of longitudinal data from multiple sources such as wearables, at-home biometric technology, and internet of things devices.

Interactive messaging

As Googles chief health officer Karen DeSalvo, M.D., MPH recently noted, the future of health is consumer-driven. AI can help doctors be ready for the shift by improving the way they and their staff communicate with their patients.

Many practices are adopting advanced communications platforms to help streamline their workflow and patient interactions. AI and machine learning will take these platforms beyond simple appointment reminders to create better patient experiences.

AI can send relevant content to the patient at the time they need it the most, which leads to patients who are better educated, more comfortable, more confident, and more engaged in meaningful conversations about their health. The result is better outcomes, and ultimately more patients and cases.

AI Is already working in health care

AI is already helping doctors do their jobs better and more efficiently. Patient diagnostics is one area where we see this already. AI can help doctors ensure that patients who need care most urgently are treated first. AI can also help staff keep track of patients in nursing homes by monitoring their conditions based on data, which takes some of the sting away from nursing shortages. It can also detect disease by analyzing data and advance treatment through machine learning.

In private practices, AI is ready to step in and help with eligibility checks, prior authorizations, insurance claims, referrals, and billing. The immediate benefit of the digital transformation to primary care doctors in their practices, however, is the technologys ability to boost patient engagement and adherence.

Also, imagine the day when the majority of your scheduling is done by a patient interacting with AI in your practice. Integrating AI technology with practice management systems will make that possible. Appointments will be made and changed all while your front office staff is checking in a patient. The result is a superior patient experience while doctors, nurses, and office staff get time back in their days for the tasks that are most important to them.

Easing patients concerns

AI is coming fast and furious, and that is undoubtedly why some of your patients will be apprehensive. The pace of change is exploding. The Wright Brothers first flight was in 1903, but commercial air travel didnt truly take off until decades later. The first human heart transplant was in 1967, while the internet revolutionized the world in a short period of time. And as my great friend Michael Longaker, M.D., co-director of the Stanford Institute for Stem Cell Biology & Regenerative Medicine recently said to me, The pace of change [in fields like] stem cell biology is rising exponentially each year.

Patients will get used to AI in their health care. It wasnt long ago that consumers were afraid to put their financial information online to complete a transaction. Now online shopping is so common that malls are half-empty even during the holiday season. Its going to take a little time until AI proves to be more effective, but in the present we can look for ways to help patients navigate information better. The right information at the right time makes a difference.

Jock Putney is the founder and CEO of WUWTA, an experience and engagement platform designed to help practices engage patients in their care and create better treatment outcomes.

Read more:
How artificial intelligence can help primary care doctorsand their ... - Medical Economics

Patients have renewed interest in STI exams after post-Covid spike – Medical Economics

Primary care physicians are being urged to encourage their patients to take a renewed interest in their sexual health after a report showed a spike in STI cases following Covid-19 lockdowns in 2022. According to experts, STI screenings were put off during the pandemic as patients prioritized other health care appointments.

The Zocdoc report, released ahead of CDC's STI Awareness Week, shows that patients have started to book more STI appointments in 2023. Zocdoc appointment booking data revealed that bookings in the first half of March 2023 were 26% higher than the same period in 2022.

The report also highlights a demographic divide, with men being more proactive about checking their sexual health than women. Millennials and Gen Z patients booked the most STI appointments, with patients in their 20s booking nearly twice as many appointments as those in their 30s. Meanwhile, seniors (65+) made up less than 1% of the bookings.

Genital warts caused by the Human Papilloma Virus (HPV) were the most common STI issue, accounting for 24% of all bookings. Genital herpes, HIV/AIDS, HPV, and hepatitis were also among the most commonly reported STIs.

Patients in Atlanta were found to be the most proactive about their sexual health, with the highest rate of STI bookings per patient. In contrast, patients in Boston, Charlotte, NC, San Francisco, and Nashville had some of the lowest booking rates.

Primary care physicians are encouraged to promote STI screenings and provide education on safe sex practices to help reduce the spread of STIs. CDC's STI Awareness Week runs through April 15th and provides a timely opportunity for health care providers to engage with their patients on this important issue.

See the original post:
Patients have renewed interest in STI exams after post-Covid spike - Medical Economics

Woman diagnosed with incurable condition after eyes turned completely white – Yahoo News

Kerrys partner plans to walk the equivalent of a half marathon with Kerrys weight on his back to raise money for treatment abroad (Collect/PA Real Life)

A woman who lost her father to suicide and was diagnosed with a brain tumour in the space of six months, having seizures up to three times a month, has taught her 10-year-old son how to call 999 and says shes only still alive for (her) kids sake.

Kerry Warburton, 35, who lives in Gainsborough, Lincolnshire, with her partner, Craig Kirkham, 36, their son, Ethan, 10, and their daughter, Ellana, 10 months, landed her dream job as a teaching assistant in December 2019,but in April 2020 she began having seizures where her eyes would turn completely white and she could no longer work.

On top of this, in July 2020 Kerrys dad died by suicide, and in January 2021 doctors found a tumour in her brain, which was causing her seizures.

One month later, doctors tried to remove her tumour by performing an open craniotomy, which made her lose her speech, and while in hospital she contracted Covid and was quarantined for 12 days partnerCraig thought she was on deaths door and doctors wereseconds away from turning off her life support, but she recovered.

Things were beginning to look up Kerry fell pregnant with her second child, Ellana, but after resuming treatment, a follow-up MRI scan revealed that her brain tumour was at stage four.

Now, Craig is planning to walk the equivalent of a half marathon to raise money for stem cell therapy which could prolong Kerrys life by three to five years.

I was at an all-time low when receiving treatment, especially after losing my dad Im only still alive now for my kids sake, Kerry said.

In December 2019, Kerry finally landed her dream job, as a teaching assistant, after going back to college as a mature student.

But in April 2020, Kerry began to have seizures, which was the first warning sign for her terminal brain tumour.

Her partner Craig said: She was shaking like mad, and her eyes rolled back in her head, and I saw foam and blood come out of her mouth.

I didnt know what the hell was going on. I was so scared, and I thought she was dying.

Story continues

The whole bed was shaking, and I thought we were having an earthquake or something.

(PA Real Life)

I had no clue what to do I was trying to push her head back into the pillow to stop her shaking, and her eyes were completely white.

Craig quickly called an ambulance, and Kerry was taken into Lincoln Hospital for tests and an MRI scan.

But Kerry was not diagnosed with anything and continued to have seizures up to three times a week, while her father died by suicide in July 2020.

Kerry said: I hit rock bottom, they took me off my seizure meds because it can cause low moods, and my seizures got worse I was having them twice a week.

In January 2021, she received more devastating news she had a five-by-five-by-five centimetre tumour in her brain.

Just a few weeks later, in February, Kerry had an open craniotomy, and was told she had stage two brain cancer,which caused her to have aphasia when a person has difficulty with their language or speech.

She explained: I lost my speech completely, it was horrible.

It was so hard for me because I wanted to speak I could speak clearly in my mind, but I couldnt get it out.

(PA Real Life)

When in hospital, she contracted Covid-19 and was quarantined for 12 days.

Craig said: I thought she was on deaths door. It was so scary they were seconds away from putting her to sleep.

It was terrifying because you couldnt go and see her.

I didnt sleep at all Id message her and check her WhatsApp constantly just to check she was alive.

Once out of hospital, Kerry found out she was pregnant and in June 2022 she gave birth to her second child, Ellana.

Just two months later, she had another MRI scan which concluded the brain tumour was terminal and stage four.

Craig said: It was scary as hell we were all happy, we had the baby, and then we were thrown back into the deep end again.

We had to travel for 55 miles for treatment again, for six weeks every single day.

Since October 2022, Kerry has been receiving radiotherapy and chemotherapy, which has caused her to lose her hair and put on over two stone.

She said: It affects my confidence I dont want to leave the house.

Kerry continues to have seizures, but they have gone down to three per month, and has even had to teach her 10-year-old son Ethan how to call an ambulance.

She said: Were scared to death that I might have a seizure when Craig is at work, so weve taught him how to call an ambulance.

Weve had to give him counselling at school to cope with me being so ill.

It was hard to teach him how to do it,I was petrified, and his school have helped.

I know it must be horrible for my son, I blame myself for him getting upset about it.

To raise money for stem cell therapy, which could extend Kerrys life by three to five years,Craig has set up a GoFundMe and plans to walk from Lincoln Castle to his house, which is the equivalent of a half marathon, with Kerrys weight, 12 stone, on his back.

Craig said: Gravity will be trying to pull me into the ground just like this tumour is trying to put her in the ground, but we are going to defy both.

Kerry added: It would just be wonderful to have the treatment, and to not worry my son anymore.

To find out more about Craigs fundraising, visit http://www.gofundme.com/f/kerry-the-white-knight.

See the original post here:
Woman diagnosed with incurable condition after eyes turned completely white - Yahoo News

Memphis Grizzlies provide details on why Steven Adams hasn’t been cleared for NBA playoffs – Yahoo Sports

The Steven Adams injury and timeline has left fans searching for answers.

A report from ESPN's Adrian Wojnarowski said that Adams is "unlikely to return" for the NBA playoffs. This came a week after Memphis Grizzlies coach Taylor Jenkins noted that Adams was beginning a reevaluation period where the team hoped he'd be able to return soon.

The Grizzlies practiced on Tuesday. Adams was at practice shooting free throws

"It's pretty confirmed he's most likely out for the playoffs," Jenkins said. "We don't have definitive words on what the next steps are. It's been an ongoing process the last couple of weeks. I think there's more dialogue still this week with doctors involved. We want to make sure Steven's in a good place."

KENNEDY CHANDLER: Kennedy Chandler tweets thanks to Memphis Grizzlies after release

ALL-AROUND GAME: What Grizzlies' Desmond Bane learned watching Danny Green, Devin Booker, Klay Thompson

GIANNOTTO: Memphis Grizzlies: Glory vs. LeBron James, Lakers or path of least resistance | Giannotto

Adams initially sprained his right PCL in January. He was expected to return in early March, but he needed a stem-cell injection that sidelined him another four weeks.

That lined Adams up for a potential reevaluation at the end of the regular season. When the Grizzlies signed Kenneth Lofton Jr. to a standard contract, it felt like an indicator of Adams' playoff status and the lack of frontcourt depth, but the Grizzlies didn't issue an official update.

"We thought we were making headway with the process and all that, but each evaluation we had with the doctors kind of revealed it's not progressing like we need it to. ... No setbacks, no reinjuries, it was just not progressing to a level. Obviously some unfortunate news, but that's why we're going to try to do everything possible to try to get the best decision possible for him," Jenkins said.

Story continues

The Grizzlies haven't ruled out surgery as an option for Adams. Jenkins said that everything remains on the table.

Xavier Tillman Sr., Jaren Jackson Jr. and Santi Aldama are expected to get the bulk of minutes at power forward and center. Aldama didn't play in the final two regular season games due to left elbow soreness, but Jenkins called it precautionary.

Aldama was a full participant in practice on Tuesday and wore a compression sleeve on his left arm.

This article originally appeared on Memphis Commercial Appeal: Steven Adams: Memphis Grizzlies give injury report for NBA playoffs

See the original post:
Memphis Grizzlies provide details on why Steven Adams hasn't been cleared for NBA playoffs - Yahoo Sports